Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Marie Skłodowska-Curie Action · Running

SHIELD Strategies for Healing Implant-associated infections and Enhancing Longevity in Devices

Coordinator
Goeteborgs Universitet, Sweden
Runs
1 September 2025 to 31 August 2029
Status
Running
EU funding
€4.7m
Total cost
—
Partners
27 organisations in 11 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101226717

What the project is doing

In the project's own words, from its summary on CORDIS.

Medical implants have revolutionised healthcare by improving quality of life through replacing missing structures, restoring function, and promoting tissue regeneration. However, implant-associated infections (IAIs) undermine these benefits, particularly in orthopaedics, otology, and odontology, leading to chronic issues and substantial healthcare costs. IAIs, exacerbated by biofilm formation and antimicrobial resistance, pose a significant public health challenge.

The SHIELD doctoral network aims to advance our understanding of IAIs, from their multifactorial pathogenesis to the development of new antibacterial biomaterials, bridging the gap between basic research and practical applications. SHIELD is structured around three scientific pillars to advance IAI control strategies in orthopaedics, otology, and odontology: regenerative medicine, biomaterial science, and translational research models.

These pillars drive research on therapeutic strategies, innovative biomaterials, and experimental proof-of-concept models. The network focuses on clinical studies, antimicrobial strategies for implants, and preclinical models to study IAI mechanisms. Our goal is to train 16 young researchers through an interdisciplinary and translational approach, combining basic research with preclinical and clinical testing. In collaboration with 27 partners from 11 countries, SHIELD brings together expertise from multiple disciplines to bridge the gap between research and real-world applications.

By developing new antimicrobial solutions for implants and conducting bench-to-bedside research, SHIELD aims to improve infection management protocols and patient care, significantly advancing the field of infection control in medical devices.

Topics

Who is involved

OrganisationCityCountryRole
Goeteborgs UniversitetGoeteborgSwedenCoordinator
Ao Forschungsinstitut DavosDavos PlatzSwitzerlandAssociatedpartner
Heraeus Medical GmbHWehrheimGermanyAssociatedpartner
Klinikum Der Universitaet RegensburgRegensburgGermanyParticipant
Technische Universitaet DresdenDresdenGermanyParticipant
Universitaet RegensburgRegensburgGermanyAssociatedpartner
Fundacion Publica Miguel ServetPamplonaSpainParticipant
Universidad Publica De NavarraPamplonaSpainAssociatedpartner
Universitat Autonoma De BarcelonaCerdanyola Del VallesSpainParticipant
Anthogyr SASSallanchesFranceParticipant
Hospices Civils De LyonLyonFranceAssociatedpartner
Phaxiam TherapeuticsLyonFranceAssociatedpartner
Universite Lyon 1 Claude BernardVilleurbanne CedexFranceAssociatedpartner
Ashland Specialties Ireland LimitedMullingarIrelandParticipant
Royal College of Surgeons in IrelandDublin 2IrelandAssociatedpartner
University College Cork - National University of Ireland, CorkCorkIrelandAssociatedpartner
University College Dublin, National University of Ireland, DublinDublinIrelandParticipant
Universita Degli Studi Di TorinoTorinoItalyParticipant
Yellow ResearchAmsterdamNetherlandsAssociatedpartner
Amicoat ASTromsøNorwayAssociatedpartner
Corticalis ASOsloNorwayAssociatedpartner
Universitetet I OsloOsloNorwayParticipant
Oticon Medical ABAskimSwedenAssociatedpartner
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomParticipant
The University of BirminghamBirminghamUnited KingdomParticipant
University of SouthamptonSouthamptonUnited KingdomAssociatedpartner
Montana State University BozemanBozemanUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI